PlainPharmaWatch

CMS Open Payments · Program Year 2024

Rattan And Associates

Rattan And Associates reported $17,268.35 across General Payments, Research, and Ownership to 92 physicians and teaching hospitals across 92 transactions.

$17.3K
All-tracks total
92
Transactions
92
Recipients
+$1.1K
General Payments vs PY2023

Rattan And Associates reported $17,268.35 across all CMS Open Payments tracks (General + Research + Ownership) to 92 physicians and teaching hospitals in Program Year 2024 - ranking #1560 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $17,268.35, averaging $187.70 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer rattan-and-associates Rattan And Associates

$17.3K · #1560/1,925 · 0.0% industry · PY2024

  • TOT $17.3K
  • RANK #1560
  • SHARE 0.0%
  • TXN 92
  • RCP 92
  • CAT 2
  • GEN $17.3K
  • ΔGEN +$1.1K
  • TOP1 10.6%
  • PY 2024

Nearest volume peer: Afaxys, Inc. ($17.3K)

Helios Cardio Inc$17.4KPromega Corporation$17.3KAfaxys, Inc.$17.3KRattan And Associates (this)$17.3KAvyxa Pharma, LLC$17.2K
All-tracks payment totals near Rattan And Associates (CMS Open Payments PY2024)

Rattan And Associates sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Rattan And Associates's CMS-reported General Payments increased by $1.1K (+7.0%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: RATTAN AND ASSOCIATESPY2023: RATTAN AND ASSOCIATESPY2024: Rattan And Associates. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$16.1KPY2024$17.3K
PY2023
$16,137.82
PY2024
$17,268.35

What the Data Shows for Rattan And Associates

$17,268.35: that is what Rattan And Associates reported in payments to 92 physicians and teaching hospitals during Program Year 2024, spread across 92 transactions ($187.70 per transaction, $187.70 per recipient). The company sits at rank #1560 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Travel and Lodging" at $13.6K, accounting for 78.9% of this company's General Payments and 24 transactions.

General Payment Breakdown by Type

Across 2 types of general payments, Rattan And Associates's largest category was "Travel and Lodging" at $13.6K - 78.9% of General Payments.

How Rattan And Associates divides its payments

Ranked by total dollars reported per category

1. Travel and Lodging$13.6K2. Food and Beverage$3.7K
Payment Type Amount Transactions
Travel and Lodging $13.6K 24
Food and Beverage $3.7K 68

Recipient Concentration in General Payments

The five largest recipient relationships account for $6,671.96 (38.6%) of $17,268.35 in this company's General Payments records across 52 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Rattan And Associates

The five named recipients with the highest reported General Payments from this company

Tammam Hanna$1.8KMatthew Kraeutler$1.6KIkechukwu Onyedika$1.2KJoshua Rollins$1.1KSarah Rees$984.06
  1. 1

    Tammam Hanna

    $1,823.27 across 5 reported transactions

  2. 2

    Matthew Kraeutler

    $1,617.68 across 3 reported transactions

  3. 3

    Ikechukwu Onyedika

    $1,156.90 across 2 reported transactions

  4. 4

    Joshua Rollins

    $1,090.05 across 3 reported transactions

  5. 5

    Sarah Rees

    $984.06 across 3 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Rattan And Associates's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Rattan And Associates.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Rattan And Associates.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Rattan And Associates's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.